Multiple Benign Symmetric Lipomatosis—A DifferentialDiagnosis of Obesity
Authors:
- 4 January 2008
- journal article
- case report
- Published by Springer Nature in Obesity Surgery
- Vol. 18 (2) , 240-242
Abstract
Multiple benign symmetric lipomatosis (MSL) is characterized by a rapid progression of multiple, symmetric nonencapsulated fat masses in face, neck, and extremities. The lipomas are thought to be the result of defective brown adipose tissue (BAT). In up to 90%, MSL is associated with chronic alcohol abuse. Prognosis depends on the concomitant presence of a neuropathy with a mortality of 25.8%. Therapeutic options are limited to alcohol abstinence and surgical interventions. We report here about a 53-year-old MSL patient who increased his body weight by 37 kg over 10 years. Multiple lipectomies were performed but disease progressed. We treated him with fenofibrates (200 mg/day). Disease progression discontinued, and circumferences of abdominal adipose tissue reduced. Fibrates, peroxisome proliferator-activated receptor alpha agonists, are pleiotropic hypolipidemic drugs and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state.Keywords
This publication has 7 references indexed in Scilit:
- Suppression of expression of muscle-associated proteins by PPARα in brown adipose tissueBiochemical and Biophysical Research Communications, 2005
- Benign symmetric lipomatosis (Launois–Bensaude syndrome)International Journal of Dermatology, 2004
- Multiple symmetric lipomatosis may be the consequence of defective noradrenergic modulation of proliferation and differentiation of brown fat cellsThe Journal of Pathology, 2002
- Multiple symmetric lipomatosis: clinical aspects and outcome in a long-term longitudinal studyInternational Journal of Obesity, 2002
- Madelung-Krankheit Eine Fallbeschreibung mit besonderer Berücksichtigung der TherapieDer Chirurg, 1997
- NEUROPATHY IN MULTIPLE SYMMETRIC LIPOMATOSISBrain, 1988
- MULTIPLE SYMMETRIC LIPOMATOSIS (LAUNOIS‐BENSAUDE SYNDROME): EFFECT OF ORAL SALBUTAMOLClinical Endocrinology, 1987